Evidence map›Paper›PMID 17465713›Full record

ArticlePharmacogenomics2007

Identifying the genotype behind the phenotype: a role model found in VKORC1 and its association with warfarin dosing.

Dana C Crawford, Marylyn D Ritchie, Mark J Rieder

Abstract read
In one paragraph

Article in Pharmacogenomics, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Measures of exposure impact genetic association studies: an example in vitamin K levels and VKORC1.Pacific Symposium on Biocomputing. Pacific Symposium on Biocomputing · 2015
    Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Dana C CrawfordVanderbilt University, Center for Human Genetics Research, 519 Light Hall, Nashville, TN 37232, USA. crawford@chgr.mc.vanderbilt.edu
Marylyn D Ritchie
Mark J Rieder

Funding

PHARMACOGENOMICS OF ARRHYTHMIA THERAPYU01HL065962 · NHLBI · VANDERBILT UNIVERSITY · PI RODEN, DAN M · 2001 to 2009
$24.8M
Pharmacogenomics of Arrhythmia TherapyU19HL065962 · NHLBI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI RODEN, DAN M · 2010 to 2014
$17.4M
Revealing Epistasis in Alzheimer DiseaseR01AG020135 · NIA · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI MARTIN, EDEN R. · 2002 to 2006
$2.7M
Genetic Factors Influencing Warfarin DoseR01NS053646 · NINDS · UNIVERSITY OF WASHINGTON · PI RIEDER, MARK J · 2006 to 2008
$1.1M
NHLBI NIH HHS HL65962NHLBI NIH HHS U01 HL065962NHLBI NIH HHS U19 HL065962NIA NIH HHS AG20135NIA NIH HHS R01 AG020135NINDS NIH HHS NS053646NINDS NIH HHS R01 NS053646
6 · The paper itself

Abstract

Genotype-phenotype studies in pharmacogenomics promise to identify the genetic factors that contribute substantially to variation in individual drug response. While most genetic association studies have failed to deliver this promise, several recent examples serve as a reminder that these associations do exist and can be identified when investigated using well-designed studies. Here, we describe the path taken to identify the association between common vitamin K epoxide reductase complex subunit 1 genetic variation and warfarin dosing in patients. We also describe the key elements that led the way, such as definition of the phenotype, confirmation of a genetic component, determination of biological plausibility and selection of genetic polymorphisms. We also describe several avenues that are yet to be explored for the specific vitamin K epoxide reductase complex subunit 1 warfarin example that can also be generalized as future directions for many genetic association studies in pharmacogenomics. These future avenues will be best explored using diverse approaches encompassing clinical, statistical and genomic methods currently being developed for genotype-phenotype studies in human populations.

Indexed as

Models, GeneticPharmacogeneticsPolymorphism, Single NucleotideAnimalsAnticoagulantsDose-Response Relationship, DrugGenotypeHumansMixed Function OxygenasesPhenotypeSpecies SpecificityVitamin K Epoxide ReductasesWarfarinAnticoagulantsMixed Function OxygenasesVitamin K Epoxide ReductasesVKORC1 protein, humanWarfarin

Identifiers

PMID17465713
PMCPMC3112050

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.